Post by Zack Zheng

--- [CNS] Orexin = The Next GLP-1? The CNS Field Just Found Its Platform Target. GLP-1 taught us one lesson: the biggest markets come from targets that expand beyond their first indication. Orexin is following the same playbook -- and the stakes are arguably bigger. The Target Orexin (hypocretin) is a hypothalamic neuropeptide controlling arousal, appetite, reward, and energy balance. When orexin neurons die, you get type 1 narcolepsy (NT1) -- irresistible daytime sleepiness and cataplexy. The field almost died with Takeda's TAK-994. Liver toxicity. Trial terminated. But new chemistry brought it back: - Takeda oveporexton (TAK-861) -- The data speaks for itself. Phase 2b (NEJM, May 2025): ESS improved 13.8 points from baseline in the best dose group vs 2.5 for placebo. Weekly cataplexy dropped from 8.76 to 2.48 -- a 72% reduction. Phase III (FirstLight + RadiantLight, July 2025): both trials met all primary and secondary endpoints with p<0.001 at week 12. No serious treatment-related adverse events. FDA accepted the NDA with Priority Review. This is on track to be the first disease-modifying therapy for NT1. - Centessa/Lilly -- Centessa's cleminorexton (ORX750) showed Phase I proof-of-concept. Eli Lilly acquired Centessa for $6.3B in May 2026. Big Pharma just placed a massive bet on orexin. - The broader field: Alkermes and others advancing orexin programs into neuropsychiatric indications. The GLP-1 Parallel | Dimension | GLP-1 | Orexin Agonists | |-----------|-------|-----------------| | Core Mechanism | Incretin -> glucose/appetite | Orexin -> arousal/energy balance | | Lead Indication | T2D, obesity, CV | NT1 narcolepsy | | Expandable Into | NASH, HF, PAD, Alzheimer's | Chronic fatigue, cognition, depression, obesity | | Market Est. | ~$130-150B (2030E) | ~$30-50B (initial CNS + niche) | The wildcard: orexin biology is deeply intertwined with energy homeostasis. Preclinical work shows OX2R signaling modulates energy expenditure and metabolic adaptation to diet -- though the directionality is complex and context-dependent. This puts orexin at the center of a bigger story: CNS-driven metabolic therapy. It won't replicate GLP-1's weight loss magnitude, but it could open an orthogonal mechanism for metabolic disease. And beyond metabolism: chronic fatigue, post-chemo fatigue, Parkinson's daytime sleepiness, depression-related low energy -- all potential expansion paths. The GLP-1 Playbook, Re-run 1. Prove mechanism + acceptable safety in a high-burden rare disease. 2. Expand rapidly into large indications. Orexin is executing step 1. Two variables determine the next decade: - Liver safety: TAK-994's ghost haunts every program. Oveporexton's Phase III safety data is the first large-scale validation that orexin agonism can be delivered without hepatotoxicity. The bar is set. - Oral PK + CNS penetration: All-day wakefulness requires steady exposure -- not stimulant-like spikes. Second-gen molecules are optimizing DMPK for sustained target engagement. The Signal Lilly paying $6.3B for Centessa's orexin program tells you everything. This isn't a niche sleep disorder play. It's a bet that orexin is the next CNS platform target -- and the race is just beginning. #Orexin #GLP1 #CNS #DrugDiscovery #Narcolepsy #Biotech #Metabolism #Takeda #Centessa #EliLilly #Neuropharmacology